Jupiter Orphan Therapeutics, Inc. (JOT) is a clinical stage specialty pharmaceutical company developing therapies for rare diseases. JOT, a Delaware Corporation with it's principal office located in Jupiter, FL, USA, was founded in the summer of 2015. In its short period of operations, JOT has assembled a very strong management and scientific team as well as developed a proprietary product for treatment of several indications.
JOT is developing treatments for various different orphan diseases such as Friedreich's Ataxia. Orphan diseases are defined in Law as a disease that affects less than 200,000 people in the USA. Other areas in the world have similar laws. Some examples of other orphan diseases are Lou Gehrig's disease and cystic fibrosis. Most of these rare diseases are very serious and must be dealt with.
JOT has developed a unique platform product, JOTROL™, which is a patented reformulation of the well known "wonder" medication resveratrol. Resveratrol is a dietary polyphenol found in grapes, red wine, berries and nuts. It has several postulated effects such as anti-cancer, anti-diabetic, cardioprotective, antioxidant, neuroprotective as well as clinically showing a prolonged lifespan in mice. It has, however, poor bio-availability in humans and at high doses cause GI side effects. JOTROL™ unlocks the true potential of resveratrol.